A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2
496
about 10 years
18+
18 sites in AZ, CT, DE +10
About this study
This trial is testing a treatment called epcoritamab, given with other medications, for people with non-Hodgkin lymphoma. The goal of it is to see how safe and well the treatment works, including any side effects that may occur.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CC-99282
- 2.Take Cyclophosphamide
- 3.Take Doxorubicin Hydrochloride [HCl]
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), epcoritamab, ibrutinib, lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), polatuzumab vedotin, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
infusion, oral (Oral Tablet), oral (Oral Capsule), oral
Primary: Number of Participants with Dose-Limiting Toxicities (DLT)
Secondary: Best Overall Response (BOR) per Investigator, Duration of response (DOR) per Investigator, Number of Participants with Progression-free survival (PFS), Overall Survival (OS), Percentage of Participants with Complete Response (CR), Time-to-response (TTR)
Oncology